Brief: Doma Perpetual Urges Pacira Biosciences Shareholders To Judge Sale Price Adequacy
21/05/2026 19:05
May 21 (Reuters) - Doma Perpetual: DOMA PERPETUAL - PACIRA BIOSCIENCES SHAREHOLDERS SHOULD DECIDE IF SALE PRICE THE CO FINDS THROUGH DISCIPLINED, BOARD‑SUPERVISED PROCESS IS ADEQUATE IN BEST INTERESTS Further company coverage: PCRX.O ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Pacira Biosciences
See all newsBrief: Pacira Biosciences Inc - Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote "For" All Of Pacira's Director Nominees
Brief: Pacira Biosciences Urges Stockholders To Vote "For" Election Of Pacira's Nominees On Blue Proxy Card
Brief: Doma Perpetual Urges Pacira Biosciences Shareholders To Judge Sale Price Adequacy
Brief: Doma Perpetual Capital Management Calls For Removal Of Pacira CEO And Strategic Sale
Brief: Pacira Biosciences Sends Letter To Stockholders Reiterating Superior Qualifications Of Its Board Nominees